The present study showed that treatment with CU06-1004 reduced the extent of liver injury and the accumulation of lipids in the liver of mice with CDAA-induced NASH, and this protection was correlated with downregulation of genes related to lipogenesis such as FAS and PPARγ. Here, FAS is linked to metabolic dysfunction-associated steatohepatitis.